Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors

Summary by The Daily News
This Story does not have an article description

1 Articles

The Daily NewsThe Daily News
Center

Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Friday, December 19, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Galveston icon

Galveston

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal